InspireMD announces abstract of 30-day results from C-Guardians U.S. IDE trial

InspireMD announced that an abstract detailing upcoming 30-day results from its C-Guardians U.S. Investigational Device Exemption, IDE, clinical trial has been accepted for presentation as a late-breaking clinical trial at the Vascular InterVentional Advances Annual Meeting, VIVA23, which is being held October 30 through November 2 in Las Vegas. Title: “30-Day Results from the C-Guardians Pivotal Trial of the CGuard Carotid Stent System.” Marvin Slosman, chief executive officer of InspireMD, stated, “We are very pleased that an abstract detailing our 30-day follow-up data from our C-Guardians IDE trial has been accepted for presentation at this year’s VIVA conference, which is among the most important gatherings of endovascular specialists each year. We believe CGuard(TM) EPS, with its novel MiroNet(TM) technology, offers next-level neuroprotection that translates into superior short- and long-term patient outcomes, something we aim to demonstrate with this important trial. We also look forward to sharing one-year data from C-Guardians in the second half of next year that, if positive, may support a Premarket Approval Application and allow us to potentially launch the CGuard Prime EPS stent system in the U.S. in the first half of 2025.”